S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout
NASDAQ:KROS

Keros Therapeutics (KROS) Stock Forecast, Price & News

$43.89
-5.07 (-10.36%)
(As of 06/9/2023 ET)
Compare
Today's Range
$42.23
$47.62
50-Day Range
$37.26
$51.01
52-Week Range
$24.38
$59.96
Volume
1.13 million shs
Average Volume
174,921 shs
Market Capitalization
$1.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$103.75

Keros Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
136.4% Upside
$103.75 Price Target
Short Interest
Healthy
3.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.90mentions of Keros Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.44) to ($5.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

189th out of 988 stocks

Pharmaceutical Preparations Industry

80th out of 479 stocks


KROS stock logo

About Keros Therapeutics (NASDAQ:KROS) Stock

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Receive KROS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KROS Stock News Headlines

H.C. Wainwright Remains a Buy on Keros Therapeutics (KROS)
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Keros Therapeutics GAAP EPS of -$1.26
Keros Therapeutics (NASDAQ:KROS) Trading 3.7% Higher
Piper Sandler Reaffirms Their Buy Rating on Keros Therapeutics (KROS)
Keros Therapeutics (NASDAQ:KROS) Shares Down 3.8%
See More Headlines

KROS Price History

KROS Company Calendar

Last Earnings
5/04/2023
Today
6/09/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KROS
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$103.75
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$100.00
Forecasted Upside/Downside
+136.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-104,680,000.00
Pretax Margin
-399.51%

Debt

Sales & Book Value

Annual Sales
$20.10 million
Book Value
$10.07 per share

Miscellaneous

Free Float
21,300,000
Market Cap
$1.30 billion
Optionable
Not Optionable
Beta
1.22

Key Executives

  • Dr. Jasbir S. Seehra Ph.D. (Age 66)
    Pres, CEO, Treasurer, & Director
    Comp: $908.09k
  • Mr. Keith C. Regnante MBA (Age 52)
    Chief Financial Officer
    Comp: $603.24k
  • Dr. Jennifer Lachey Ph.D. (Age 49)
    Chief Scientific Officer
    Comp: $604.74k
  • Mr. Christopher Rovaldi M.Sc. (Age 48)
    Chief Operating Officer
  • Ms. Esther Cho J.D.
    Head of Legal & Corp. Sec.
  • Ms. Robin Wagner
    VP of HR
  • Dr. Simon Cooper MBBS (Age 52)
    Chief Medical Officer













KROS Stock - Frequently Asked Questions

Should I buy or sell Keros Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KROS shares.
View KROS analyst ratings
or view top-rated stocks.

What is Keros Therapeutics' stock price forecast for 2023?

5 brokers have issued 12-month price targets for Keros Therapeutics' stock. Their KROS share price forecasts range from $100.00 to $110.00. On average, they expect the company's share price to reach $103.75 in the next year. This suggests a possible upside of 136.4% from the stock's current price.
View analysts price targets for KROS
or view top-rated stocks among Wall Street analysts.

How have KROS shares performed in 2023?

Keros Therapeutics' stock was trading at $48.02 on January 1st, 2023. Since then, KROS stock has decreased by 8.6% and is now trading at $43.89.
View the best growth stocks for 2023 here
.

When is Keros Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our KROS earnings forecast
.

How were Keros Therapeutics' earnings last quarter?

Keros Therapeutics, Inc. (NASDAQ:KROS) issued its quarterly earnings results on Thursday, May, 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.14) by $0.12. During the same quarter in the prior year, the business posted ($1.01) earnings per share.

What other stocks do shareholders of Keros Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Keros Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Cloudera (CLDR), CVS Health (CVS), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA), Karyopharm Therapeutics (KPTI), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Pfizer (PFE).

When did Keros Therapeutics IPO?

(KROS) raised $75 million in an initial public offering (IPO) on Wednesday, April 8th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

What is Keros Therapeutics' stock symbol?

Keros Therapeutics trades on the NASDAQ under the ticker symbol "KROS."

Who are Keros Therapeutics' major shareholders?

Keros Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (13.70%), BlackRock Inc. (5.67%), Price T Rowe Associates Inc. MD (3.90%), State Street Corp (3.19%), Candriam S.C.A. (2.52%) and First Light Asset Management LLC (2.01%). Insiders that own company stock include Christopher Rovaldi, Claudia Ordonez, Jennifer Lachey, Julius Knowles, Ran Nussbaum and Richard K Prins.
View institutional ownership trends
.

How do I buy shares of Keros Therapeutics?

Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Keros Therapeutics' stock price today?

One share of KROS stock can currently be purchased for approximately $43.89.

How much money does Keros Therapeutics make?

Keros Therapeutics (NASDAQ:KROS) has a market capitalization of $1.30 billion and generates $20.10 million in revenue each year. The company earns $-104,680,000.00 in net income (profit) each year or ($4.40) on an earnings per share basis.

How can I contact Keros Therapeutics?

Keros Therapeutics' mailing address is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. The official website for the company is www.kerostx.com. The company can be reached via phone at 617-314-6297 or via email at jbalanova@troutgroup.com.

This page (NASDAQ:KROS) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -